Bob DubridgeEVP of Research at Maverick Therapeutics
Bob received his B.A. in Biology from the University of California at San Diego and his Ph.D. in Genetics from Stanford University. After completing his postdoctoral studies at Genentech, Bob was one of the founding scientists of Cell Genesys, Inc. He went on to become the Director of the Massively Parallel Signature Sequencing (MPSS) project at Lynx Therapeutics and his group was responsible for setting up the first next generation sequencing platform. From 1999 to 2010 Bob led the New Technologies and Antibody Engineering groups at Eos and then PDL Biopharma. In 2010 he founded Full Spectrum Genetics (FSG) to develop a novel, high throughput mutation profiling system to create detailed structural maps of protein binding sites using single substitution libraries. He joined Maverick at its formation to develop a novel class of conditionally activated T-cell engagers in 2017.